Drug Profile

SS 109

Alternative Names: 109 - Jiangsu Gensciences; SS-109

Latest Information Update: 27 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Jiangsu Gensciences
Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Immunoglobulin Fc fragments; Recombinant fusion proteins
Mechanism of Action Factor VIII replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

12 Oct 2023 Phase-I/II clinical trials in Haemophilia A in China (Parenteral) (NCT06010953)
12 Oct 2023 Phase-I/II clinical trials in Haemophilia B in China (Parenteral) (NCT06010953)
30 Aug 2023 Jiangsu Gensciences plans a phase Ib/II trial for Haemophilia A and Haemophilia B in China (Parenteral) in September 2023 (NCT06010953)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com